# ImmunityBio Drug Approved for Common Bladder Cancer

> FDA approves ImmunityBio's Anktiva for more common bladder cancer type.
- Title: ImmunityBio Drug Approved for Common Bladder Cancer | Shortify
- Summary: FDA approves ImmunityBio's Anktiva for more common bladder cancer type. FDA grants ImmunityBio's Anktiva expanded use for papillary tumors in bladder cancer…
- Keywords: immunitybio, anktiva, bladder cancer, fda approval, papillary tumors, bladder cancer treatment, Los Angeles Business Journal
- Source: Los Angeles Business Journal — https://labusinessjournal.com/healthcare/expanded-use-for-immunitybio-drug
- Author: Hannah Welk
- Published: 2026-10-26T07:01:56+00:00
- Read time: 1 min
- Topics: immunitybio, anktiva, bladder cancer, fda approval, papillary tumors, bladder cancer treatment, business, local
## FDA Approval for Anktiva
ImmunityBio's Anktiva now approved by FDA for more common bladder cancer type with papillary tumors.
## Earlier Than Expected
FDA approval came months ahead of deadline after initial 2024 approval for rare bladder cancer form.
## Stock Reaction
Stock rose 4% on Oct 14 but fell back to Sept 28 low since then.
## Expanded Use Process
FDA rejected expanded use in early 2025, requiring more data before Jan 6, 2027 decision.
## Key takeaway

FDA grants ImmunityBio's Anktiva expanded use for papillary tumors in bladder cancer after months of review.